Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies

Executive Summary

Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic
Advertisement

Related Content

GSK/Corixa Bexxar Video Draws FDA Warning Letter
GSK/Corixa Bexxar Video Draws FDA Warning Letter
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Advertisement
UsernamePublicRestriction

Register

PS042072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel